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Placental Perivascular Cells
for Human Muscle Regeneration
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Perivascular multipotent mesenchymal progenitors exist in a variety of tissues, including the placenta. Here, we
suggest that the abundant vasculature present in the human placenta can serve as a source of myogenic cells to
regenerate skeletal muscle. Chorionic villi dissected from the mid-gestation human placenta were first trans-
planted intact into the gastrocnemius muscles of SCID=mdx mice, where they participated in muscle regener-
ation by producing myofibers expressing human dystrophin and spectrin. In vitro-cultured placental villi
released rapidly adhering and migratory CD146+CD34CD45CD56 cells of putative perivascular origin that
expressed mesenchymal stem cell markers. CD146+CD34CD45CD56 perivascular cells isolated and puri-
fied from the placental villi by flow cytometry were indeed highly myogenic in culture, and generated dys-
trophin-positive myofibers, and they promoted angiogenesis after transplantation into SCID=mdx mouse
muscles. These observations confirm the existence of mesenchymal progenitor cells within the walls of human
blood vessels, and suggest that the richly vascularized human placenta is an abundant source of perivascular
myogenic cells able to migrate within dystrophic muscle and regenerate myofibers.
Introduction
The placenta is a transitory organ that developsduring pregnancy at the feto-maternal interface. It con-
sists of 3 distinct layers: the amnion and chorion, both of fetal
origin, and the maternal decidua. The chorionic villous pla-
centa contains a rich vasculature to supply oxygen and nu-
trients to the fetus [1–4] via chorionic villi that are the vascular
projections structured by an outer layer of trophoblastic cells
and inner part of fetal blood vessels. These numerous blood
vessels result from neovascularization followed by active
angiogenesis. Capillaries initially form de novo in the chorionic
villi from hemangiogenic progenitors, which in turn engender
endothelial networks through successive steps of differentia-
tion and proliferation under the influence of trophoblast cells
[5,6]. Angiogenesis continues during placentation with de-
velopment of both endothelial and perivascular cells [2,7,8].
The placenta is rich in stem=progenitor cells. While the am-
nion has been reported to contain epiblast-derived pluripotent=
multipotent stem cells (aka human amniotic epithelial cells)
that express embryonic stem cell markers [4,9–14], placenta-
derived mesenchymal stem cells (MSCs) have been isolated
from all 3 layers (amnion [3,15,16], chorion [17–19], and de-
cidua [3,20]). Human trophoblastic stem cells were isolated
from the human villous placenta over 4 decades ago [7], and
yet the most recent studies on placental MSC still rely on
mundane, indirect isolation strategies, on a par with the lack
of knowledge on the identity of these cells [17–19,21,22].
We previously identified microvascular pericytes as a
major and ubiquitous source of human MSC in various fetal
and adult organs [23], including fetal placenta. While addi-
tional cell populations may act as mesenchymal progenitors
in particular tissues such as fat [24], pericytes represent an
unique and consistently detectable population of cells in all
organs, which express a specific set of surface antigens, in-
cluding the cell adhesion molecule CD146 [25] and the pro-
teoglycan NG2, and lack endothelial and hematopoietic cell
markers. On the basis of this distinct cellular signature, we
showed that pericytes can be reliably isolated as CD146þ
CD34CD56CD45 cells from various organs, including
placenta [23]. Muscle-derived pericytes belong to a collec-
tion of distinct myogenic stem=progenitor cells [26–28],
and efficiently regenerate skeletal muscle. Yet, pericytes ex-
hibit robust myogenic potential independently of their tissue
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origin, as pericytes sorted from pancreas, adipose tissue, and
placenta are also myogenic [23,25].
In the present work, we characterized in detail placenta
villus cell subsets and their myogenicity. First, we docu-
mented the myogenic potential in vivo of intact, undissoci-
ated villus fragments. We then evaluated in detail the
intrinsic properties of migration, adhesion, and MSC phe-
notype of expanded pericyte-like and nonpericyte popula-
tions. We finally compared the in vitro and in vivo myogenic
potentials of freshly isolated placenta pericytes and non-
pericyte populations, as well as their angiogenic capacities
in vivo. Together, our findings suggest the abundant exis-
tence of highly migratory and myogenic perivascular mes-
enchymal progenitor cells within the placental vasculature.
On the basis of these results, we propose placenta as a con-
venient, rich source of newly generated blood vessels suit-
able for cellular therapeutic applications.
Materials and Methods
Isolation of purified villous fragments
from the human fetal placenta
After informed consent, in compliance with the Institu-
tional Review Board (protocol number 0506176) at the Uni-
versity of Pittsburgh, placentas were obtained from mid-
gestation (18–23 weeks) interrupted pregnancies. Bundles of
chorionic anchoring (stem) villi were separated from the
chorionic plate and spread out using forceps to separate in-
dividual villi from each other (Fig. 1A, b–d). The villi were
washed multiple times in phosphate buffered saline (PBS;
Sigma, St Louis, MO) until blood cells and tissue debris were
removed (Fig. 1A, e). Terminal parts of the villi were cut off
to avoid the presence of any decidual tissue (Fig. 1A, f).
Dissected villi were cut into *1-mm3 pieces (Fig. 1A, g) for
in vitro culture=assay or transplantation into mouse muscles.
Immunofluorescence staining of placental
blood vessels
For in toto immunofluorescence staining (Fig. 1B), dissected
villi were placed on glass slides and immunostained. Villus
fragments were successively incubated with unconjugated
mouse anti-human CD34 (BD Biosciences, 1:100) followed by
goat anti-mouse-biotin (Dako, 1:500), and streptavidin-Cy3
(Sigma, 1:500). Next, anti-CD146-FITC (AbD Serotec, 1:50)
was added for 2 h at room temperature (RT). 40,6-Diamidino-
2-phenylindole (DAPI; Molecular Probes, 1:2000) was added
to stain nuclei. Tissue was washed in PBS after each incuba-
tion. Photographs were captured using a Nikon Eclipse
TE2000-U microscope and Snap Advanced software.
For cross-sectional staining (Fig. 1C), dissected villi were
embedded in tissue freezing medium (Triangle Biomedical
Sciences), frozen in liquid nitrogen vapors, cryosectioned at
6–7 mm, and immunostained, as previously described [23,29].
Frozen sections were fixed in a mixture of cooled (208C)
methanol and acetone (1:1) for 5min before staining. Sections
were blocked using 5% goat serum for 1 h at RT and incu-
bated overnight at 48C with either unconjugated mouse anti-
human CD34 (BD Biosciences), CD56 (BD Pharmingen),
CD133 (Miltenyi Biotec), CD144 (Santa Cruz Biotechnology),
CD146 (BD Biosciences), or KDR (vascular endothelial
growth factor receptor-2; Santa Cruz Biotechnology, all
1:100). Then, goat anti-mouse-biotin (Dako) and streptavidin-
Cy3 (Sigma) were incubated sequentially. Alternately, sec-
tions were stained in addition with anti-alpha-smooth
muscle actin-FITC (aSMA; Sigma, 1:200), actin-CD31-FITC
(Santa Cruz Biotechnology, 1:50), or actin-CD146-FITC (AbD
Serotec) followed by DAPI staining. Photographs were cap-
tured using a Nikon Eclipse TE2000-U microscope or
Olympus FLUOVIEW FV1000.
For immunocytostaining, cells grown out of placenta villi
were plated in 48-well plates at 2104 cells=cm2 and fixed using
a mixture of cooled (208C) methanol and acetone (1:1) for
5min. Cells were then incubated overnight in unconjugated
rabbit anti-human PDGF receptor-b (PDGFR-b; Santa Cruz
Biotechnology), mouse anti-human NG2 (BD Biosciences),
CD31 (Chemicon), CD144 (BenderMedSystems), or CD146 (BD
Biosciences) (all 1:100). PDGFR-b staining was revealed using
donkey anti-rabbit-Alexa 488 (Molecular Probes, 1:500) sec-
ondary antibody. For all othermouse anti-humanunconjugated
antibodies, cells were sequentially incubated with biotinylated
goat anti-mouse (Dako) and streptavidin-Cy3 (Sigma). Ad-
ditionally, some cells were costained with anti-aSMA-FITC
(Dako), anti-CD34-FITC (Miltenyi Biotec, 1:50), anti-CD146-
FITC (AbD Serotec), or anti–vonWillebrand factor–FITC (vWF,
US Biological, 1:100), followed by DAPI staining.
Villus fragment culture
Dissected villi were cultured intact on 24-well plates with or
without 0.2% gelatin coating either in muscle proliferation
medium (PM) containing Dulbecco’s modified Eagle’s me-
dium (Invitrogen), 10% fetal calf serum (FCS, Invitrogen), 10%
horse serum (Sigma), 1% chick embryo extract, and 1%
penicillin=streptomycin (PS; Invitrogen), or in endothelial
growth medium-2 (EGM2; Lonza). When outgrowing cells
reached over 80% confluency, the villi pieces remaining intact
were carefully removed, transferred into, and subsequently
cultured on new gelatin-coated or noncoated plates. This
procedure was repeated till the 5th outgrowth. Monolayers of
outgrown cells were further expanded additional 3–5 pas-
sages in alpha-MEM (Invitrogen) supplemented with 20%
FCS and 1% PS, and then used for cell sorting or analyses.
Myogenic differentiation in vivo
Four pieces of dissected villi (1mm3 each) were trans-
planted into a surgical pocket within the gastrocnemius
muscle of a dystrophic SCID=mdx mouse. Animals were
sacrificed 2 and 4 weeks after transplantation. Harvested
muscles were frozen in cooled 2-methylbutane between
508C and 608C, and cryosectioned at 6–8 mm. Sections
were fixed in a mixture of cooled (208C) methanol and
acetone (1:1) for 5min before staining. Nonspecific antibody
binding was blocked with 5% goat serum and permeablized
0.1% Triton in PBS. Sections were incubated overnight at 48C
with mouse anti-human dystrophin (hDys3, Novocastra,
1:20), anti-spectrin (Novocastra, 1:100), anti-lamin A=C
(Novocastra, 1:100), or anti-human nuclear antigen (Chemi-
con, 1:50) antibodies, followed by goat anti-mouse-biotin
(Dako) and streptavidin-Cy3 (Sigma).
Freshly isolated CD146CD34þCD45CD56, CD146þ
CD34CD45CD56, CD146CD34CD45CD56, and
unsorted cells from fetal placenta villi were injected into the
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gastrocnemius muscles of dystrophic SCID=mdx mice. Each
muscle received 2104 cells and was harvested 4 weeks post-
transplantation. Muscles were processed as described above
and stained with rabbit antidystrophin antibody (Abcam,
1:100) followed by secondary donkey anti-rabbit antibody
coupled to Alexa 488 (Molecular Probes, 1:500).
Myogenic differentiation in vitro
Cells were plated at 2104 cells=cm2 in muscle PM. At
60%–70% confluence, the culture medium was half diluted
in Dulbecco’s modified Eagle’s medium (to reduce the se-
rum concentration). Culture medium=serum concentration
was successively reduced daily until a concentration of 2%
was reached. The medium was then renewed every other
day until multinucleated cells were observed. Differentiated
cells were fixed in cooled methanol (208C) for 5min be-
fore staining. Cells were permeablized with 0.3% Triton in
PBS. Mouse anti-human desmin (Sigma, 1:100) was incu-
bated with cells overnight at 48C. Goat anti-mouse biotin
(Dako) and streptavidin-Cy3 (Sigma) were then incubated
sequentially.
Flow cytometry analysis and cell sorting
Outgrown villi cells were trypsinized, washed, and
stained with mouse anti-human CD44-PE (Invitrogen),
CD73-PE (BD Biosciences), CD90-PE (Immunotec), CD105-PE
FIG. 1. Isolation and char-
acterization of human fetal
placental villi. (A) Isolation of
chorionic villi from the 22-
week placenta (a, b). A por-
tion of fetal placenta (c, circled
in a and b) has been separated
from the chorionic plate,
stretched (d), and washed
several times in PBS (e). Dis-
sected villi (f) were cut into
1-mm3 fragments (g) for
transplantation and in vitro
analysis. (B) In toto immuno-
fluorescence staining of dis-
sected placental villi. CD34þ
endothelial cells (a, c, red) are
surrounded by CD146þ peri-
vascular cells (b, c, green). (C)
Immunofluorescence staining
on cryosections of dissected
placental villi. Blood vessels
and capillaries are composed
with endothelial cells expres-
sing CD34 (a, red), CD144 (b,
red), and CD31 (c, green) and
perivascular cells expressing
CD146 (green in a, b, e, and f;
red in d) or aSMA (d, green).
Enlarged squared area in b
(b1–b4) shows CD144þ en-
dothelial cells (arrows) and
CD146þ pericytes (arrow
heads). Nonvascular cells ex-
press CD56 (c, red), aSMA (d,
green), and KDR (e, red).
Trophoblast layers express
CD133 (f, red). Scale bars are
10mm in A; 50 mm in B and C.
aSMA, alpha-smooth muscle
actin. Color images available
online at www.liebertonline
.com=scd.
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(Invitrogen), and CD146-FITC (AbD Serotec) (all 1:100). Each
incubation was performed for 20min at 48C.
Alternatively, 2 g of chorionic villi was minced and sus-
pended in 20mL of collagenases type I, II, and IV (all at
1mg=mL; Sigma). After a 30-min incubation on a rotating
device (150 rpm) at 378C, trypsin was added (final concen-
tration 0.25%, Invitrogen) for another 10min. Cells were fil-
tered through a 70-mm cell strainer and washed free of
enzymes. The cell pellet was re-suspended in red cell lysis
buffer for 15min at RT. After another centrifugation, cells
were incubated for 30min at 48C with mouse anti-human
CD34-PE (DAKO), CD56-PE-Cy7 (BD Biosciences), CD45-
APC (BD Biosciences), CD146-FITC (Serotec) (all 1:50), and
7-aminoactinomycin D (7-AAD; BD Biosciences; 1:100). Cells
were analyzed and sorted using a FACSAria flow cytometer
(Becton-Dickinson) with FACSDiva software (Becton-Dick-
inson).
Migration (wound healing) assay in vitro
Cells were plated in 12-well plates at a density of 5105
cells=well in a-MEM supplemented with 20% FCS, 1% PS,
and cultured until confluent. A single straight wound was
created in the center of the resulting monolayers using a
sterile plastic pipette tip [30]. Cells were washed twice in PBS
and cultured in a-MEM supplemented with 2% FCS, 1% PS
to reduce proliferation. Each population was cultured in
triplicate wells and photographed (3 pictures per well) at day
0 (postwound) and day 1 (24 h later). Average distance at
day 0 (D0) was calculated from the mean of 4 distances be-
tween cells on either side of the wound per picture. Average
distance at day 1 (D1) was calculated from the mean of at
least 10 distinct distances between cells per picture. Migra-
tion rate (%) was calculated according to the following
equation: [(D0D1)=D0]100.
Adhesion assay
Cells were plated at 2105 cells=well in 6-well plates,
which were either uncoated, or precoated overnight with
type I collagen, 0.2% gelatin, 2 mg=cm2 fibronectin, or
1mL=well undiluted FCS. One hour later, floating cells were
removed and adherent cells were fixed in 1% paraformal-
dehyde for 15min at RT, and then stained with DAPI (Mo-
lecular Probes). Five images were randomly captured from
each well to provide the average numbers of cells attached in
each condition (n¼ 3).
Real-time quantitative reverse transcriptase-
polymerase chain reaction
Total RNA was extracted from 2104 or more cells using
the Nucleospin RNA kit (Clontech). cDNA was synthesized
with SuperScript II reverse transcriptase (Invitrogen), ac-
cording to manufacturer’s instructions. cDNA and primers
were added to SYBR Green PCR master mix (Applied Bio-
systems) according to manufacturer’s instructions. The
quantitative analysis was performed by the Genetics Core
Laboratory at the University of Pittsburgh. All data were
normalized to human cyclophilin, which was used as an
internal control. The primer sequences are listed in Supple-
mentary Table S1 (Supplementary Data are available online
at www.liebertonline.com=scd).
Statistics
Data are summarized as average standard deviation.
Statistical comparison between groups was performed using
2-tailed Student’s t-test (95% confidence interval). P values
are listed in the figures.
Results
Isolation and characterization of placental villi
Over 20 individual placentas were used for this project.
Developmental stages ranged between 17 and 23 weeks of
gestation (20.4 1.9 weeks, n¼ 18) and weights averaged
27.1 10.6 g (n¼ 6). Bundles of chorionic villi attached to the
chorionic plate were easily distinguishable (Fig. 1A, a, b).
Fetal blood vessels located near the surface and inside of
villi were detected by in toto immunostaining, revealing
the whole vascular anatomy (Fig. 1B, c) constituted of lu-
minal endothelial CD34þ cells (Fig. 1B, a) and perivascular
CD146þcells (Fig. 1B, b). Observation of immunostained
villus cross sections confirmed fetal blood vessels to be
composed of CD34þCD144þ endothelial cells surrounded
by CD146þ perivascular cells (Fig. 1C, a, b, enlarged squared
area of b shown in b1–b4). The inner part of chorionic villi
contained a large number of small fetal blood vessels, stained
for CD34 (1-C, a), CD144 (1-C, b), CD31 (1-C, c) (endothelial
cells), and CD146 (1-C, a, b, d-f) (perivascular cells). Non-
vascular cells (smooth muscle, mesenchymal, or fibroblastic
cells) were diversely positive for CD56 (1-C, c), aSMA (1-C,
d), and KDR (1-C, e). The outer layer of the villi is composed
of 2 cell layers, the syncytiotrophoblast and cytotrophoblast,
that are positively stained for CD133 (Fig. 1C, f).
Intramuscular transplantation of placental villi
As a first attempt to assess the inherent myogenic poten-
tial of human placenta blood vessels, we transplanted intact
dissected villus fragments (Fig. 1A, g) into surgical pockets
made in the gastrocnemius muscles of dystrophic SCID=mdx
mice. The presence of human cells and myofibers was
investigated at 2 and 4 weeks after transplantation. Obser-
vation of cross sections through host muscles revealed that
human placental implants retained their native structure at
2 weeks post-transplantation (Fig. 2A–F, dashed circles). Hu-
man cells were identified inside the implants by detection of
human-specific proteins, human nuclear antigen (hNA, Fig.
2E), and human lamin A=C (Fig. 2F). Human placenta par-
ticipated in muscle regeneration, as assessed by the detection
of human dystrophin-positive (hDys3þ) myofibers not only
close to the engrafted area (Fig. 2B, dashed square), but also
in more distant regions, suggesting the migration of im-
planted human cells (Fig. 2B, lined square shown at higher
magnification in 2-C).
Human myofibers detected by human dystrophin (Fig.
2G) and spectrin expression (Fig. 2H) were typically clus-
tered and mostly small in diameter with single centered
nuclei, which are distinctive features of early muscle regen-
eration (Fig. 2G, I). To demonstrate that these newly re-
generated myofibers are truly of human origin, and not an
intermediate product of cell fusion, we costained chimeric
mouse muscle sections with antibodies to human-specific
lamin A=C and spectrin. Human lamin A=C, shown in pink,
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is colocalized in central nuclei with DAPI staining (blue), and
human spectrin (red) is exclusively expressed on the sarco-
lemma of myofibers (Fig. 2I) [31]. SCID=mdx mice that un-
derwent sham surgery without receiving human villus
segments were used as negative controls, in which muscle
sections did not show any positive signal after incubation
with the anti-human antibodies (data not shown).
Cell outgrowth in cultures of total placental villi
After revealing the myogenic potential of total placental
villi in vivo, we proceeded to explore the progenitor cell
characteristics of various cell populations residing in pla-
cental villi, including CD146þ perivascular cells. Small pie-
ces (1mm3) of intact placental villi (Fig. 1A, g) were cultured
on gelatin-coated or noncoated plates in EGM2 or muscle
PM. Tissue adherence often failed on noncoated plates but
was significantly enhanced in the presence of gelatin (or
collagen type IV). Five to 7 days later, outgrowth of cells was
first observed, and then sustained. Replating villus frag-
ments for additional outgrowth followed by the first out-
growth step led to faster cell outgrowing and higher
proliferation on gelatin-coated plates in EGM2 than all other
conditions (Supplementary Fig. S1). Cells outgrown from
villus fragments in EGM2 were of polygonal morphology
and proliferated rapidly (Fig. 3A, upper row; Supplementary
Video S1), whereas cells outgrown in PM were spindle
shaped, resembling fibroblasts (Fig. 3A, lower row).
Proliferation was measured using the live cell imaging
system, a fully automatic robotic videomicroscopy system
that captures images of cell growth every 12 h for 6 days.
EGM2 significantly enhanced cell proliferation rate, as
compared to PM (Fig. 3B). There were no major differences
in growth rate between cells cultured in coated or noncoated
plates. However, the addition of extracellular matrix induced
the growth of different cell populations. When dissected villi
FIG. 2. Myogenicity of placenta fragments transplanted into SCID=mdx mouse skeletal muscles. (A) Bright-field picture of
cross-sectioned SCID=mdx mouse muscle that received human placenta villi (dashed circle) 2 weeks earlier. (B, C) Immuno-
fluorescence staining of the same section as (A) for human dystrophin (hDys3, red) and lamin A=C (red). The proximal region
(dashed square) includes high numbers of hDys3þ fibers, fewer of which are present in the distal area (lined square, shown in C).
(D) Transplantation area after 2 weeks. (E) Human nuclear antigen (hNA, red) detection in squared area in D. (F) Lamin A=C
(red) staining of adjacent section confirms the human origin of the implant (circled area). (G–I) Immunofluorescence staining
of chimeric mouse dystrophic muscle. Human myofibers generated from the transplanted human placenta fragments express
human dystrophin (hDys3, G, red) or human spectrin (hSpectrin, H, red). (I) Staining of hSpectrin (myofiber membrane) and
lamin A=C (nuclei) confirms that spectrinþ myofibers were contributed by human cells. Nuclei were stained with Dapi
(blue). Scale bars are 500 mm in A and B; 50 mm in C–I. Color images available online at www.liebertonline.com=scd.
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were cultured in EGM2 on gelatin-coated plates, CD146 and
NG2 double-positive cells—ie, pericytes [23]—were present,
which was not observed in noncoated plates (Fig. 3C). We
therefore favored the outgrowth and propagation of peri-
cytes from dissected placental villi using gelatin-coated
plates and EGM2. Cells outgrown in these conditions were
immunocytostained in 48-well culture plates. Most cells ex-
pressing CD146 were also positive for PDGFR-b and NG2,
further indicating their perivascular origin [23,26,27,32,33].
Few CD146-positive cells expressed aSMA, and cells out-
grown from villi rarely expressed the endothelial cell mark-
ers CD31, CD34, CD144, and vWF (Fig. 3D).
MSC marker expression by cultured villus cells
On the basis of our immunocharacterization of cells out-
grown from placenta villi, only 2 major cell populations could
emerge under our culture conditions (EGM2 in gelatin-coated
plates): (1) cells expressing pericyte markers and (2) cells
lacking pericyte markers. Using fluorescence-activated cell
sorting (FACS), we applied our previously published gating
strategy [23] to isolate both populations. Cells outgrown from
placenta villi were sorted as CD146þCD34CD45CD56
pericytes and CD146CD34CD45CD56 nonpericyte
cells. As observed by immunofluorescence staining, few or no
endothelial cells could be detected (Fig. 3). Similarly, hardly
any CD45þ and CD56þ cells were present in our cultures.
Consequently, no major cell population was excluded as
per this purification strategy that allowed us to eliminate
remaining endothelial and hematopoietic cells.
Thereafter, sortedCD146þCD34CD45CD56 (CD146þ)
cells and CD146CD34CD45CD56 (CD146) cells were
further cultured up to passage 5 and analyzed by flow
cytometry. Both populations strongly and homogeneously
expressed the MSC markers CD105 and CD44. CD73 expres-
sion was detected in 57.2% and 77.4% of expanded CD146þ
and CD146 cells, respectively (Fig. 4B). Yet, analysis of CD90
expression revealed a major difference between both popula-
FIG. 3. In vitro outgrowth of placental villi. (A) Cells grown for 12 days from villus fragments exhibit different
morphologies according to the culture medium used, EGM2, or muscle PM. (B) Proliferation measured using the Live Cell
Imaging System. Cells cultured in EGM2 grow and proliferate more rapidly than those cultured in PM, whereas culture plate
coating made no difference (G, gelatin; NC, not coated). (C) FACS analysis of out-growing cells in EGM2 medium on
noncoated (upper panel) and gelatin-coated (lower panel) plates. (D) Immunocytostaining of cells cultured in EGM2 on gelatin-
coated plates. The perivascular cell markers PDGFRb and NG2 are coexpressed with CD146. aSMA-, CD34-, vWF-, and
CD144-expressing cells were rarely observed. Scale bars in A andD are 100 mm. EGM2, endothelial growth medium-2; FACS,
fluorescence-activated cell sorting; PM, proliferation medium. Color images available online at www.liebertonline.com=scd.
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tions. Over 60% of CD146þ cells were positive for CD90 ex-
pression, whereas <5% of CD146 cells were (Fig. 4A, B). We
examined brachyury mRNA, an early mesodermal stem cell
marker, in these 2 cell populations. Higher levels of brachyury
mRNAwere detected in CD146þ cells (Fig. 4C, lane 2) than in
CD146 cells (Fig. 4C, lane 3). GAPDHmRNA expressionwas
used as an internal control (Fig. 4C, lanes 4 and 5).
Migration and adhesion of CD146þ and CD146
villus-derived cells
Cells outgrown from placenta villi as described above were
sorted on expression of CD146 (and absence of CD34, CD45,
and CD56) for further evaluation in terms of migration and
adherence. CD146þ, CD146, and unsorted cells were plated
and grown to over 90% confluency. A single wound was
created in the center of the cell monolayer (764 152.6mm,
n¼ 12) to observe empty space filling by migrating cells
(Fig. 5A, day 0). After 24h, CD146þ cells demonstrated
quantitatively higher migratory efficiency compared to both
CD146 and total unsorted cells (Fig. 5A, day 1, and 5B).
Adhesion regulates multiple aspects of cell life via a vari-
ety of molecules and ligands [30,34–37]. To test the behavior
of villus-derived cells in the presence of different adhesion
molecules, sorted CD146þ and CD146 cells were seeded on
different extracellular matrix substrates. Both populations
were plated, in equal numbers, onto either noncoated, FCS
saturated, collagen-, gelatin-, or fibronectin-coated culture
plates. One hour later, unattached cells were removed and
adherent cells were counted. CD146þ cells adhered faster
FIG. 4. MSC marker expression by cultured placental cells. (A) Flow cytometry analysis of CD146þCD34CD45CD56
(CD146þ cells, upper row) and CD146CD34CD45CD56 (CD146 cells, lower row) outgrown cells for expression of MSC
markers after 4 passages. Dotted lines with white background indicate isotype controls and the numbers in the histograms
are percentages of antigen-expressing cells. (B) Average numbers of MSC marker-expressing cells within CD146þ and
CD146 populations (n¼ 3). (C) Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of CD146þ and CD146
cells for expression of brachyury. From left: M, size marker; 1, brachyury in human fetal muscle (positive control); 2,
brachyury in CD146þ cells; 3, brachyury in CD146 cells; 4, GAPDH in CD146þ cells; 5, GAPDH in CD146 cells. MSC,
mesenchymal stem cell; PCR, polymerase chain reaction.
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than CD146 cells to all tested extracellular coating materi-
als: collagen, gelatin, and fibronectin. Conversely, CD146
cells attached slightly faster on noncoated plates and those
saturated with FCS (Fig. 5C).
To further comprehend the distinct cell migration and
adhesion properties of CD146þ cells, compared to their
CD146counterparts, we studied their expression of re-
lated genes. As assessed by real-time quantitative reverse
transcriptase (RT)-polymerase chain reaction, CD146þ cells
expressed integrin-alpha (Int-a) 1, 2, 4, 5, 6, integrin-beta 1 (Int-
b1) andmetalloproteinase-2 at higher levels than CD146 cells
(Fig. 5D). Interestingly, Int-a5 (a subcomponent of the fibro-
nectin receptor) was expressed in excess of 9-fold higher, and
Int-a6 (a subcomponent of the collagen receptor)was expressed
4-fold more by CD146þ cells than CD146 cells. Strikingly,
metalloproteinase-2 is expressed >25-fold higher by CD146þ
cells, consistent with our observations that CD146þ cells mi-
grate more actively than CD146 cells (Fig. 5D).
In vitro myogenesis from freshly sorted
placental cells
After enzymatic digestion, placenta villus cells were pu-
rified by FACS into CD146þCD34CD45CD56 (CD146þ
cells), CD146CD34þCD45CD56 (CD34þ cells), and
CD146CD34CD45CD56 (CD34CD146 cells) cell
populations. Villus cell suspensions included 31 11.7%
CD45þ hematopoietic cells (n¼ 3). After gating out CD45þ
and CD56þ cells, CD34þ endothelial=adventitial cells
(3.5 2.6%, n¼ 8) and CD146þ perivascular cells (1.68
0.78%, n¼ 8) could be clearly delineated (Fig. 6A). CD146þ
CD34þCD45CD56 endothelial cells accounted for <1%
or were absent. In postsort culture, perivascular cells devel-
oped elongated cytoplasmic arms, whereas endothelial cells
typically exhibited a polygonal morphology, consistent with
our previous observations [23] (Fig. 6B).
Culture-expanded cells were plated at a density of 2104
cells=cm2 and cultured under conditions promoting myo-
genic differentiation. Fifteen days later, both CD34þ and
CD146þ populations included significantly higher numbers
of desminþ cells (Fig. 6C, D) than unsorted or CD34
CD146 cells. However, the morphology of newly generated
desminþ cells differed between these populations. CD146þ
cells formed elongated, occasionally multinucleated myofi-
bers, whereas CD34þ cells generated exclusively mononu-
cleated, scattered desminþ cells (Fig. 6C).
To confirm the differentiation into the myogenic cell
lineage, we further examined mRNA expression of CD56
FIG. 5. Migration and adhesion of CD146þ and CD146Cultured placental cells. (A) Migration=wound healing by
CD146þCD34CD45CD56 (CD146þ), CD146CD34CD45CD56 (CD146), and unsorted (total) outgrown cells. At
day 0 a single wound was generated and the distances of empty space were measured at days 0 and 1. Scale bars are 500 mm.
(B) Migration rates between distinct cell populations. Average migration rates are 88% (CD146þ), 44.5% (CD146), and
45.1% (total population), n¼ 4. (C) Adhesion assay on CD146þ and CD146 sorted outgrown cells using collagen-, gelatin-,
fibronectin-, non-, or FBS-coated plates, n¼ 8. (D) Quantitative RT-PCR analysis on CD146þ and CD146 cells. Fold changes
of relative mRNA expression by CD146þ to CD146 cells of, from left, integrin-alpha 1, 2, 4, 5, 6 (Int-a1, Int-a2, Int-a4, Int-a5,
Int-a6), integrin-beta 1 (Int-b1), and metalloproteinase-2.
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(N-CAM), a commonly used marker of myoblasts [28,38–40],
in vascular cells (CD34þ and CD146þ), nonvascular cells
(CD34CD146), culture-expanded unsorted cells (total),
and freshly isolated unsorted cells (case 1 and case 2, re-
presenting 2 distinct donors). Human fetal muscle was used
as a positive control. CD56 was upregulated after myogenic
differentiation in all populations. However, CD146þ cells
showed the highest CD56 expression level postdifferentia-
tion, which was even substantially higher than in human
fetal muscle (Fig. 6E, far right).
In vivo myogenesis and promotion of local
angiogenesis by freshly sorted placenta cells
We next examined the myogenic and angiogenic capacities
of the different freshly purified placental cell populations by
injections into gastrocnemius muscles of immunodeficient
dystrophic (SCID=mdx) mice. We injected per muscle 1104
freshly sorted CD146CD34þCD45CD56 endothelial,
CD146þCD34CD45CD56 perivascular, CD146CD34
CD45CD56 nonvascular, or unsorted (total) cells. Two
FIG. 6. In vitro myogenic differentiation of purified placental cell subsets. (A) Cell sorting from enzymatically digested
placentae villi. After gating-out CD45þ and CD56þ cells, CD146CD34þCD45CD56 (CD34þ), CD146þCD34
CD45CD56 (CD146þ), and CD146CD34CD45CD56 (CD34CD146) cells were separated by FACS. Numbers in
the quadrants represent percentages of cells. (B) FACS purified or unsorted (total) cells after 6 days in culture. (C) Desmin
(red) expression after 15 days of myogenic differentiation. (D) Numbers of nuclei in desmin-positive cells after in vitro
myogenic differentiation. (E) Quantitative RT-PCR analysis of CD56 expression in sorted populations before (Pre-
differentiation) and after (Postdifferentiation) in vitro myogenic differentiation. Cases 1 and 2 indicate 2 different fetal
placentas. Human fetal muscle (fMuscle, far right) was used as a positive control. Scale bars in B and C are 50 mm. Color
images available online at www.liebertonline.com=scd.
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weeks postinjection, host muscles were harvested, cryosec-
tioned, and stained with antibodies against both human and
mouse dystrophin and vWF.
Both CD146þ and CD34þ sorted vascular cells generated
clusters of dystrophinþ myofibers after injection into
SCID=mdx mice. Injection of nonvascular cells only resulted
in the formation of low numbers of separated single myofi-
bers. Unsorted cells were injected as a control and gave rise
to an intermediate number of myofibers, compared to vas-
cular and nonvascular cell populations (Fig. 7A).
Tissue regeneration after injury is positively correlated
with angiogenesis=neovascularization [41]. Blood vessels
supply the damaged area with nutrients and oxygen, and
support the migration of progenitor cells from the bone
marrow or other sites [28,30,41–45]. All human cell-injected
SCID=mdx mouse muscles contained more blood vessels
than PBS-injected muscles (Fig. 7B). Interestingly, CD146þ
cell injection resulted in significantly higher numbers of
blood vessels than that of the other populations. Mid-gesta-
tion human fetal muscle (fMuscle) was processed in the same
manner for comparison (Fig. 7C).
We have no evidence that perivascular cells could differ-
entiate into endothelial cells in our transplantation setting.
However, perivascular cells produce angiogenic factors such
as basic fibroblast growth factor, heparin binding-epidermal
growth factor-like growth factor (HB-EGE), keratinocyte
growth factor, and vascular endothelial growth factor [25]
and have the ability to organize blood vessel development
from the host endothelial cells [46,47]. On the basis of pub-
lished results and our own knowledge, perivascular cells
promote angiogenesis via secretion of angiogenic factors or
by recruiting domestic endothelial cells but are less likely to
trans-differentiate into endothelial cells.
Discussion
Satellite cells can naturally regenerate skeletal myofibers
lost to exercise, disease, or injury. Besides this well-
characterized, committed muscle-residing progenitor, sev-
eral multipotent mesodermal stem cells localized within
skeletal muscle (myo-endothelial cells) or of broader tissue
distribution (mesoangioblasts, MSCs, and pericytes) are also
experimentally myogenic, although a genuine role for these
cells in muscle homeostasis has not yet been demonstrated
[25]. We have indeed previously observed that pericytes
sorted to homogeneity by flow cytometry from multiple
human organs, including the placenta, are immediately
myogenic in culture or after xenogeneic transplantation into
injured or diseased muscles [23].
We have now explored in much more detail the myogenic
potential of human placental pericytes: first, because the
naturally shed placenta is of unlimited availability as a
source of therapeutic cells; second, because the abundant
vasculature of placental villi can be mechanically dissected as
an intact network of diversely sized blood vessels, as illus-
trated by Fig. 1. Successful transplantation of human pla-
cental villi under the kidney capsule of immunodeficient
mice has been previously reported [48]. Here we trans-
planted dissected human chorionic villi intramuscularly into
immunodeficient dystrophic mice, and numerous human
FIG. 7. Myogenesis and angiogenesis in placental cell-engrafted SCID=mdx mouse muscles. (A) Dystrophin (green) de-
tection on frozen sections of SCID=mdx mouse gastrocnemius muscles that received unsorted (total),
CD146CD34þCD56CD45 (CD34þ), CD146þCD34CD56CD45 (CD146þ), and CD146CD34CD56CD45
(CD34CD146) freshly sorted cells. (B) von Willebrand factor (vWF, green) staining on frozen sections of SCID=mdxmouse
muscles that received PBS, unsorted (Total), CD146CD34þCD56CD45 (CD34þ), CD146þCD34CD56CD45
(CD146þ), or CD34CD146CD56CD45 (CD34CD146) cells. Human fetal muscle (fMuscle) was processed identically
as a positive control. (C) Numbers of blood vessels expressing vWF in dystrophic muscles that received different human
placental cells. Scale bars in A and B are 50 mm. Color images available online at www.liebertonline.com=scd.
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myofibers were generated around the implants. This result is
important as it shows that perivascular cells do not exhibit
myogenic potential—and possibly other developmental
abilities—exclusively when dissociated from adjacent endo-
thelial cells and purified by flow cytometry [23,26]. This
should be at difference with the adipogenic potential of fat
tissue perivascular cells, which is inhibited by association
with endothelial cells [49]. Alternatively, as an intermediate
possibility, placental perivascular cells responded to the
compromised muscle environment by migrating away from
the endothelium, which stimulated a previously repressed
myogenic potential.
Besides pericytes, did other placental cells participate in
the observed myogenesis? Immunostaining of isolated pla-
centa vessels in toto revealed the expected presence of en-
dothelial cells and pericytes, which express CD34 and
CD146, respectively. In our optimized version of the villous
explant culture [50,51], 2 major cell populations grew from
placental villi: pericyte-like CD146þCD34CD45CD56
cells and CD146CD34CD45CD56 nonpericytes. CD34þ,
CD31þ, and CD144þ endothelial cells were rapidly over-
grown by these 2 cell populations. Both CD146þ and
CD146 cell subsets outgrown from placental villi were
sorted by FACS and further cultured separately. The pericyte
origin of CD146þ cells was confirmed by their coexpression
of other pericyte as well as MSC markers [23], and their
multilineage mesodermal developmental potential (Supple-
mentary Fig. S2). On the basis of these observations, and
their high level of brachyury mRNA expression, CD146þ
pericyte-like cells grown from placental villi appeared to be
closely related to bone marrow-MSC [52], and likely repre-
sent the myogenic cell contingent evidenced in the above
described transplantation experiments. To further document
the affiliation of these cultured cells, both CD146þCD34
CD45CD56 and CD146CD34CD45CD56 cells—as
well as CD146CD34þCD45CD56 cells—were detected
and sorted by FACS from the native placenta and injected
intramuscularly into immunodeficient dystrophic mice.
Perivascular (CD146þCD34CD45CD56) and, to a far
lesser extent, CD146CD34þCD45CD56 cells gave rise to
differentiated dystrophin-expressing myofibers in the im-
munodeficient hosts, but only limited numbers of human
myofibers were produced by CD146CD34CD45CD56
cells, confirming the observations made on cultured villus
blood vessels. Not only were placenta pericytes myogenic,
they also significantly improved local angiogenesis, in
agreement with the observation that multipotent placental
MSCs (hPMSCs) can be isolated from term human placenta
that are angiogenic [53]. This further suggests that MSCs and
their ancestors can also mediate tissue repair by secreting
growth factors [22].
The results reported here confirm and extend our con-
clusions regarding the existence in human organs of peri-
cytes endowed with multilineage mesodermal potential, at
the origin of MSCs once culture-adapted [23,25,33,
54]. Clearly, the CD146þCD34CD45CD56 pericytes
described around placental microvessels have a definitive
advantage over neighboring cell populations in terms
of growth and migration in vitro, and are the most potent
as regard myogenicity. Pericytes are not, however, the only
myogenic cells present in human placenta, as we have also
detected power to generate myofibers within CD146
CD34þCD45CD56 cells. Most likely, these latter cells
belong to the pool of perivascular MSC ancestors of the same
phenotype we have recently identified in the tunica adven-
titia of human arteries and veins as the stem cell equivalents
in larger vessels of microvascular pericytes (Corselli et al.,
submitted for publication). We show in essence that the
richly vascularized placenta is a convenient and abundant
source of blood vessel associated stem cells.
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